Development of novel amyloid imaging agents based upon thioflavin S

Current Alzheimer Research

Volumn 2, Issue 2, 2005, Pages 109-114

  Wei, Jingjun ^a   Wu, Chunying ^a   Lankin, David ^a   Gulrati, Anil ^a   Valyi Nagy, Tibor ^a   Cochran, Elizabeth ^b   Pike, Victor W ^c   Kozikowski, Alan ^a   Wang, Yanming ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Alzheimer's disease; Amyloid; Congo red; Thioflavin S; Thioflavin T

Indexed keywords

AMYLOID; CONGO RED; DIRECT YELLOW 7; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GRAY MATTER; HUMAN; HYDROPHILICITY; NEUROIMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE DIAGNOSIS; STRUCTURE ACTIVITY RELATION;

AMYLOID; DIAGNOSTIC IMAGING; FLUORESCENT DYES; HUMANS; TECHNOLOGY, PHARMACEUTICAL; THIAZOLES;

EID: 20844451743     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/1567205053585864     Document Type: Conference Paper

References (29)

1. Sair HI, Doraiswamy PM and Petrella JR. In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 46: 93-104 (2004).
2. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 3: 519-527 (2004).
3. Mathis CA, Wang Y and Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 10: 1469-1492 (2004).
4. Selkoe DJ. Imaging Alzheimer's amyloid. Nat Biotechnol 18: 823-824 (2000).
5. Petrella JR, Coleman RE and Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 226: 315-336 (2003).
6. Morris JC and Rubin EH. Clinical diagnosis and course of Alzheimer's disease. Psychiatr Clin North Am 14: 223-236 (1991).
7. Kratzsch T, Peters J and Frolich L. [Etiology and pathogenesis of Alzheimer dementia]. Wien Med Wochenschr 152: 72-76 (2002).
8. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430: 631-639 (2004).
9. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766 (2001).
10. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3: 824-828 (2002).
11. Hardy JA and Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185 (1992).
12. Zhang J, Yarowsky P, Gordon MN, Di Carlo G, Munireddy S, van Zijl PC et al. Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med 51: 452-457 (2004).
13. Kung HF, Kung MP, Zhuang ZP, Hou C, Lee CW, Plossl K et al. Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol 5: 418-426 (2003).
14. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 100: 12462-12467 (2003).
15. Klunk WE, Engler H, Nordberg A, Bacskai BJ, Wang Y, Price JC et al. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am 13: 781-789, ix (2003).
16. Styren SD, Hamilton RL, Styren GC and Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 48: 1223-1232 (2000).
17. 11C-labelling of (E,E)-1-(3′,4′-dihydroxystyryl)-4- (3′-methoxy-4′-hydroxystyryl)benzene for PET imaging of amyloid deposits. J. Labelled Compounds and Radiopharmaceuticals 45: 647-664 (2002).
18. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP et al. Imaging A Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systemically Administered Congo Red Derivative. J Neuropathol Exp Neurol 61: 797-805 (2002).
19. Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ and Lee VM. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97: 7609-7614 (2000).
20. Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C and Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 123: 12740-12741 (2001).
21. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12: 584-595 (2004).
22. Burns J, Pennock CA and Steward PJ. The specificity of the staining of amyloid deposits with thioflavine T. J Pathol Bacteriol 94: 337-344 (1967).
23. Klunk WE, Wang YM, Hung GF, Debnah ML, Holt DP and Mathis CA. Uncharged Thioflavin-T Derivative Bind to Amyloid-beta Protein with High Affinity and Readily Enter the Brain. Life sciences 69: 1471-1484 (2001).
24. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML and Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754 (2003).
25. Zhuang ZP, Kung MP, Hou C, Skovronsky DM, Gur TL, Plossl K et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 44: 1905-1914 (2001).
26. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319 (2004).
27. Barrio JR, Huang SC, Cole GM, Sayamurthy NM, Petric A, Phelps ME et al. PET Imaging of Tangles and Plaques in Alzheimer's With a highly Hydrophitic Probe. J. Labelled Compounds and Radiopharmaceuticals 42 (suppl.): S194-195 (1999).
28. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM. Siddarth P et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24-35 (2002).
29. Janus C, Chishti MA and Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim Biophys Acta 1502: 63-75 (2000).